Methoden und Zusammensetzungen welche Thalidomid zur Behandlung von Krebs und idiopathischer pulmonaler Fibrose enthalten

Méthodes et compositions comprenant du thalidomide pour le traitement du cancer et de la fibrose pulmonaire idiopathique

Methods and compositions using thalidomide for the treatment and management of cancers and idiopathic pulmonary fibrosis

Abstract

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (30)

    Publication numberPublication dateAssigneeTitle
    US-3536809-AOctober 27, 1970Alza CorpMedication method
    US-3598123-AAugust 10, 1971Alza CorpBandage for administering drugs
    US-3845770-ANovember 05, 1974Alza CorpOsmatic dispensing device for releasing beneficial agent
    US-3916899-ANovember 04, 1975Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
    US-4008719-AFebruary 22, 1977Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
    US-4810643-AMarch 07, 1989Kirin- Amgen Inc.Production of pluripotent granulocyte colony-stimulating factor
    US-4994443-AFebruary 19, 1991The Children's Medical Center CorporationInhibition of angiogenesis
    US-4999291-AMarch 12, 1991Amgen Inc.Production of human pluripotent granulocyte colony-stimulating factor
    US-5001116-AMarch 19, 1991The Children's Medical Center CorporationInhibition of angiogenesis
    US-5059595-AOctober 22, 1991Bioresearch, S.P.A.Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
    US-5073543-ADecember 17, 1991G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
    US-5120548-AJune 09, 1992Merck & Co., Inc.Swelling modulated polymeric drug delivery device
    US-5134127-AJuly 28, 1992University Of KansasDerivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
    US-5229496-AJuly 20, 1993Immunex CorporationAnalogs of human granulocyte-macrophage colony stimulating factor
    US-5354556-AOctober 11, 1994Elan Corporation, PlcControlled release powder and process for its preparation
    US-5385901-AJanuary 31, 1995The Rockefeller UniversityMethod of treating abnormal concentrations of TNF α
    US-5391485-AFebruary 21, 1995Immunex CorporationDNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
    US-5393870-AFebruary 28, 1995Immunex CorporationAnalogs of human granulocyte-macrophage colony stimulating factor
    US-5528823-AJune 25, 1996The Whitaker CorporationMethod for retaining wires in a current mode coupler
    US-5580755-ADecember 03, 1996Amgen Inc.Human pluripotent granulocyte colony-stimulating factor
    US-5591767-AJanuary 07, 1997Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
    US-5593990-AJanuary 14, 1997The Children's Medical Center CorporationMethods and compositions for inhibition of angiogenesis
    US-5629327-AMay 13, 1997Childrens Hospital Medical Center Corp.Methods and compositions for inhibition of angiogenesis
    US-5639476-AJune 17, 1997Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
    US-5643915-AJuly 01, 1997Andrulis Pharmaceuticals Corp.Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
    US-5674533-AOctober 07, 1997Recordati, S.A., Chemical And Pharmaceutical CompanyPharmaceutical composition for the controlled release of moguisteine in a liquid suspension
    US-5712291-AJanuary 27, 1998The Children's Medical Center CorporationMethods and compositions for inhibition of angiogenesis
    US-5733566-AMarch 31, 1998Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
    US-6071948-AJune 06, 2000The Children's Medical Center CorporationMethods and compositions for inhibition of angiogenesis
    US-6114355-ASeptember 05, 2000D'amato; RobertMethods and compositions for inhibition of angiogenesis

NO-Patent Citations (36)

    Title
    "Introduction to Pharmaceutical Dosage Forms", 1985, LEA & FEBIGER
    "Physicians' Desk Reference", 2002, pages: 1755 - 1760
    "Physicians' Desk Reference", 2003, pages: 1153 - 1157
    "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING
    "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
    BLASCHKE, ARZNEIMITTELFORSCHUNG, vol. 29, 1979, pages 1640 - 1642
    CASINI ET AL., FARMACO ED. SCI., vol. 19, 1964, pages 563
    COSTA, P.T. ET AL., BLOOD, vol. 92, 1998, pages 235B
    D'AMATO M. ET AL., PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 4082 - 4085
    EHRENPREIS, E.D. ET AL., GASTROENTEROLOGY, vol. 117, 1999, pages 1271 - 1277
    EMENS, L.A. ET AL., CURR. OPINION MOL. THER., vol. 3, no. 1, 2001, pages 77 - 84
    FOLKMAN ET AL., SCIENCE, vol. 221, 1983, pages 719
    GILMAN ET AL.: "Goodman and Gilman's: The Pharmacological Basis of Therapeutics", MCGRAW HILL
    I. D. FRATTA ET AL., TOXICOL. APPL. PHARMACOL., vol. 7, 1965, pages 268
    JENS T. CARSTENSEN: "Drug Stability: Principles & Practice", 1995, MARCEL DEKKER, pages: 379 - 80
    KOCH, H.P., PROG. MED. CHEM., vol. 22, 1985, pages 165 - 242
    MARX, G.M. ET AL., PROC. AM. SOC. CLIN. ONCOLOGY, vol. 18, 1999, pages 454A
    MCCANN, J., DRUG TOPICS, 21 June 1999 (1999-06-21), pages 41 - 42
    MCHUGH, S.M. ET AL., CLIN. EXP. IMMUNOL., vol. 99, 1995, pages 160 - 167
    MCHUGH, S.M. ET AL., CLIN. EXPER. IMMUNOL., vol. 99, 1995, pages 160 - 167
    MOLLER, D.R. ET AL., J IMMUNOL., vol. 159, 1997, pages 5157 - 5161
    MOLLER, D.R. ET AL., J. IMMUNOL., vol. 159, 1997, pages 5157 - 5161
    MOREIRA, A.L. ET AL., J. EXP. MED., vol. 177, 1993, pages 1675 - 1680
    MOREIRA, A.L. ET AL., J. EXPR. MED., vol. 177, 1993, pages 1675 - 1680
    PENICHET, M.L.; MORRISON, S.L., J. IMMUNOL. METHODS, vol. 248, 2001, pages 91 - 101
    ROITT, I.; BROSTOFF, J; KALE, D.: "Immunology", 1993, pages: 17.1 - 17.12
    SHEALY ET AL., CHEM. INDUS., 1965, pages 1030
    SINGHAL, S. ET AL., NEW ENGLAND J. MED., vol. 341, no. 21, 1999, pages 1565 - 1571
    STOCKDALE: "Medicine", vol. 3, 1998
    SUEOKA NAOKO ET AL: "Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenic mice", CYTOKINE, vol. 10, no. 2, February 1998 (1998-02-01), pages 124 - 131, XP002528060, ISSN: 1043-4666
    SZLOSAREK P W ET AL: "Tumour necrosis factor alpha: a potential target for the therapy of solid tumours", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 4, no. 9, 1 September 2003 (2003-09-01), pages 565 - 573, XP004809882, ISSN: 1470-2045
    TAYLOR ET AL., NATURE, vol. 297, 1982, pages 307
    U.S. PHARMACOPEIA (USP) 25-NF20, 2002
    VASILIAUSKAS, E.A. ET AL., GASTROENTEROLOGY, vol. 117, 1999, pages 1278 - 1287
    VASSALLO ROBERT ET AL: "Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition", CHEST, vol. 122, no. 3, September 2002 (2002-09-01), pages 1093 - 1096, XP002527702, ISSN: 0012-3692
    ZWART, D., ARZNEIM.-FORSCH., vol. 16, no. 12, 1966, pages 1688 - 1689

Cited By (0)

    Publication numberPublication dateAssigneeTitle